Post-approval studies (Phase 4)Study completedNCT01250951
What this trial is testing
This Study Will Evaluate Efficacy and Safety of Deferasirox in Patients With Myelodysplastic Syndromes (MDS), Thalassemia and Rare Anemia Types Having Transfusion-induced Iron Overload.
Who this might be right for
Myelodysplastic SyndromeThalassemia
Novartis Pharmaceuticals 111